Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss of US$45.09 million a year earlier. Alongside this return to quarterly profitability and higher six-month revenues, management narrowed expected full-year 2026 net loss to US$42 million–US$34 million and modestly raised its revenue outlook to US$802 million–US$806 million, signaling increased...

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NeoGenomics (NEO) is back in focus after second quarter earnings on 28 July 2026 reported quarterly profitability, revenue of US$201.66 million, and updated full year guidance that raised revenue expectations and narrowed projected net loss. See our latest analysis for NeoGenomics. NeoGenomics shares traded at US$15.84 on 31 July 2026, with a 90 day share price return of 78.18% and a 1 year total shareholder return of 181.85%, which points to strong recent momentum despite a weaker 5 year...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 17% over the past six months while the S&P 500 was up 8.3%.

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported second-quarter 2026 earnings that surpassed Wall Street expectations and raised its full-year financial guidance.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and

NeoGenomics Inc (NEO) reports robust revenue growth and margin expansion, while addressing challenges in its pharma segment and raising full-year guidance.

NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing. Total second-quarter revenue rose 11% ye

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on year to $201.7 million. The company expects the full year’s revenue to be around $804 million, close to analysts’ estimates. Its non-GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

NeoGenomics stock has delivered a strong 134.1% return over the past year, yet its current checks suggest the shares may be priced at a premium rather than standing out as a clear bargain. Over the last 1 year, NeoGenomics has returned 134.1%, which puts extra focus on whether the recent enthusiasm is already reflected in the price. The launch of the FDA approved PTEN IHC companion diagnostic for prostate cancer can support expectations for NeoGenomics' testing volumes and commercial reach,...

NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion diagnostic that helps identify prostate cancer patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP. See our latest analysis for NeoGenomics. The FDA-cleared PTEN IHC CDx arrives at a time when NeoGenomics’ share price has shown strong short term momentum, with a 30-day share price return of 40.75% and a 1-year total shareholder return of 134.13%, although the 3- and 5-year total...

Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.